Search - tctmd.com

Displaying 81 - 100 of 1328

Sort: Relevancy | Date

TCT 401: Impact of >12-Month Versus =12-Month Dual Antiplatelet Therapy on Long-Term Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention

Presentation TCT 2024

TCT 401: Impact of >12-Month Versus =12-Month Dual Antiplatelet Therapy on Long-Term Outcomes After Chronic Total Occlusion Percutaneous Coronary Intervention

Presenter: Yao Jiang

October 27, 2024

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Presentation TCT 2024

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Presenter: IFTIKHAR CH

October 27, 2024

APPRAISE ATP Highlights the Trade-offs of Antitachycardia Pacing

News Daily News

APPRAISE ATP Highlights the Trade-offs of Antitachycardia Pacing

October 09, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

News Industry News

Pi-Cardia Receives FDA Market Clearance for ShortCut™

October 01, 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

News Conference News ESC 2024

NOTION-3: PCI Before TAVI Lowers MACE Risks in Patients With Significant CAD

Michael O'Riordan

September 01, 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

August 31, 2024

Dropping Aspirin From Post-LAAO Regimens Seems Like a Good Idea

News Daily News

Dropping Aspirin From Post-LAAO Regimens Seems Like a Good Idea

August 27, 2024

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

Scientific Statement Reviews Current Antithrombotic Options in PAD

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

August 26, 2024

What’s Going to Be Hot at ESC 2024

News Opinion Editor's Corner

What’s Going to Be Hot at ESC 2024

August 23, 2024

DES Best for In-Stent Restenosis, but DCBs Also Viable

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

August 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

August 01, 2024

Similar Safety, Efficacy With Leadless vs Transvenous Pacemakers at 2 Years in Medicare Population

News Daily News

Similar Safety, Efficacy With Leadless vs Transvenous Pacemakers at 2 Years Post-TAVI

Yael L. Maxwell

July 26, 2024

Ideal Aspirin Dose in Secondary Prevention Doesn’t Differ Much by Sex

News Daily News

Ideal Aspirin Dose in Secondary Prevention Doesn’t Differ Much by Sex

July 11, 2024

Semaglutide Has Similar Benefits in Women and Men With HFpEF

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

June 26, 2024

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

News Daily News

Weight-Loss Drug Tirzepatide Reduces Severity of Obstructive Sleep Apnea

Michael O'Riordan

June 25, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.